-
The FDA Showing Valeant Some Love With Recent Drug Approvals
Wednesday, July 20, 2016 - 1:58pm | 292Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock got a boost on Wednesday after the U.S. Food and Drug Administration (FDA) approved the company's RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. Valeant said in a press release that it...
-
Carl Icahn's New Stake In Allergan
Tuesday, May 31, 2016 - 10:16am | 250Read More...The billionaire investor confirmed through his Twitter account that he has acquired a "large position" in Allergan plc Ordinary Shares (NYSE: AGN). Shares of Allergan were trading higher by more than 2.5 percent after Tuesday's opening bell. Icahn also said in a statement is he is...
-
Eli Lilly Says It Will Launch 20 New Products Through 2023
Tuesday, May 24, 2016 - 9:41am | 306Read More...Eli Lilly and Co (NYSE: LLY) detailed in a presentation to the investment community its outlook for new product launches through 2023. Eli Lilly said that it has the potential to launch a total of 20 new products in the 10-year period beginning in 2014 and extending through 2023. In addition, the...
-
Here's Why NephroGenex Plunged 40% On Wednesday
Wednesday, February 24, 2016 - 3:29pm | 142Read More...Shares of NephroGenex Inc (NASDAQ: NRX), a nano-cap pharmaceutical company that focuses on treatment for kidney diseases, plunged more than 40 percent on Wednesday after the company announced a business update. NephroGenex said it will pause a clinical program of its product candidate oral...
-
Mallinckrodt Reports Better-Than-Expected Q1, Raises Guidance
Tuesday, February 2, 2016 - 8:54am | 263Read More...Shares of Mallinckrodt PLC (NYSE: MNK) were trading higher by nearly 6 percent early Tuesday morning after the company reported its first quarter results. Mallinckrodt earned $2.09 per share in the first quarter on revenue of $914.80 million. Wall Street analysts were expecting the company to...
-
Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'
Wednesday, January 27, 2016 - 3:16pm | 259Read More...According to The Boston Globe, Massachusetts Attorney General Maura Healey wrote a letter to Gilead Sciences, Inc. (NASDAQ: GILD) which suggested her office could initiate legal action. The Boston Globe noted that Healey's letter was dated January 22 and delivered to Gilead's CEO John...
-
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
Tuesday, September 29, 2015 - 3:27pm | 494Read More...Shibani Malhotra of Nomura is expecting the specialty pharmaceutical and generics "merger frenzy" will continue into 2016. Malhotra argued that companies with access to capital are now "more likely" to pursue deals, be it either friendly or hostile. However, Malhotra cautioned that investor...
-
Getting The Word Out To Cannabis Users: A Chat With BudgetWeed CEO Marlon Fuller
Tuesday, July 15, 2014 - 3:57pm | 1095Read More...Editor's note on July 28, 2015: Dr. Marlon Fuller is no longer affiliated with BudgetWeed.com. BudgetWeed.com is a Charlotte, North Carolina-based cannabis industry product and service locater. The website, according to its founder and CEO Dr. Marlon Fuller is “a fusion between Yelp and...
